Merck takes on new challenges

Williams, Dede; Gibson, Jane
January 2007
ICIS Chemical Business;1/15/2007, Vol. 2 Issue 49, p12
Trade Publication
The article reports on a tender offer launched by Merck KGaA for the outstanding equity of Swiss-based biopharmaceuticals producer Serono. Merck also confirmed tentative plans to sell its generics business. The German drugs and chemicals group now controls 84% of Serono's shares and 89% of voting rights.


Related Articles

  • Teva to Buy Merck KGaA's Generics?  // Chemical Week;5/9/2007, Vol. 169 Issue 16, p6 

    The article reports that Teva Pharmaceutical Industries is likely to be selected to acquire the generic pharmaceutical business of Merck KGaA. Merck KGaA invited offers for the business but says it has not made a final decision to divest. Aggressive bidding had pushed the price of the generics...

  • Merck KGaA Launches Merck Serono SA and Plans to Divest Generics Business. Van Arnum, Patricia // Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p26 

    The article presents various developments in the pharmaceutical operation of Merck KGaA. The company has completed its acquisition of the majority stake of Serono SA. On the other hand, the company announces that it is considering the divestiture of Merck Generics. Meanwhile, it is planning to...

  • Swiss buy is too high, say analysts. Davis, Nigel // ICIS Chemical Business;9/25/2006, Vol. 1 Issue 36, p8 

    This article reports on the decision of Merck KGaA to acquire Swiss biopharmaceuticals company Serono. According to analysts, Merck KGaA shares fell nearly 6% on the news. The acquisition of Serono would transform Merck's ethical pharmaceuticals business and create a leader in biological...

  • German M&A continues apace. Williams, Dede; Gibson, Jane // ICIS Chemical Business;10/2/2006, Vol. 1 Issue 37, p10 

    The article reports on the plan of Merck KGaA to acquire 64.5% of equity and 75.5% of voting rights of Swiss biopharmaceuticals producer Serono for €10.6 billion. After incorporating Serono, Merck will have overall sales of €7.7 billion, including €3.6 billion in...

  • Merck generics sale to create powerhouse? Mirasol, Feliza // ICIS Chemical Business Americas;1/15/2007, Vol. 271 Issue 2, p24 

    The article reports on the plan of Merck KGaA to sell its generics business. The generics business of the company ranks among the leading generics operations worldwide. Its rivals include major players Teva, Novaris and Barr Pharmaceuticals. The leading contender for the business is Ranbaxy, the...

  • Merck KGaA eyes pharma acquisitions in the US. ALPEROWICZ, NATASHA // Chemical Week;12/2/2013, Vol. 175 Issue 30, p11 

    The article reports on the plan of Merck Kgaa, a pharmaceutical company, to open collaborations and acquisitions, and strengthen the company's presence in the prescription pharmaceuticals industry in the U.S. Topics include the statement of company board member Stefan Oschmann on about 50% sales...

  • Merck flexes muscles. Williams, Dede; Gibson, Jane // ICIS Chemical Business;3/12/2007, Vol. 2 Issue 57, p13 

    The article reports on the announcement by retiring Merck chairman Michael Roemer that the company intends to remain an integrated chemicals-pharma player. He confirmed that the group is talking to potential buyers for its generics business. He revealed that chemicals continue to drive company...

  • Collaborations Between Biotech And Pharmaceutical Companies: May 25 - June 28, 2007.  // BioWorld Financial Watch;7/2/2007, Vol. 15 Issue 27, p3 

    The article provides information on several deals between biotech and pharmaceutical companies. Adenosine Therapeutics LLC has signed an option agreement with Novartis AG for the A2B receptor antagonist program. Ambrx Inc. and Merck Serono SA have reached an exclusive licensing agreement for the...

  • Corporate venture funds chase early-stage deals. Mitchell, Peter // Nature Biotechnology;May2009, Vol. 27 Issue 5, p403 

    This article discusses the rising prominence of venture capital funds that are instigated by pharmaceutical companies. As the economic recession has dampened the availability of traditional private equity, these companies are beginning to serve as benefactors for start-up biotechnology firms....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics